^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) +
    Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens

    Published date:
    11/04/2020
    Excerpt:
    There was no significant difference in the overall survival (median OS, 33 vs. 38 months, p=0.28...the 3-year survival rates were 45% and 63% in TP53MT and TP53wt, respectively.
    DOI:
    https://doi.org/10.1182/blood-2020-142012